Aetion
April 23, 2020
Webinar: Real-world evidence for regulatory decision-making, in the era of COVID-19
As the COVID-19 pandemic shifts our work and life realities, biopharma executives are asking how they can efficiently direct resources to advance their R&D programs.
Real-world evidence (RWE) offers potential as a complement to randomized controlled trials (RCTs) to answer regulatory questions on not only safety, but on effectiveness as well.
In this webinar, Jeremy Rassen, Sc.D., Co-Founder, President, and Chief Science Officer of Aetion, and Sebastian Schneeweiss, M.D., Sc.D., Professor of Medicine and Epidemiology at Harvard Medical School, discuss how to use RWE to support development and post-marketing studies. They explore best practices, potential pitfalls, and how to ensure success in today’s rapidly changing environment—including use of a platform for decision-ready evidence generation.
Watch the webinar
Real-world evidence (RWE) offers potential as a complement to randomized controlled trials (RCTs) to answer regulatory questions on not only safety, but on effectiveness as well.
In this webinar, Jeremy Rassen, Sc.D., Co-Founder, President, and Chief Science Officer of Aetion, and Sebastian Schneeweiss, M.D., Sc.D., Professor of Medicine and Epidemiology at Harvard Medical School, discuss how to use RWE to support development and post-marketing studies. They explore best practices, potential pitfalls, and how to ensure success in today’s rapidly changing environment—including use of a platform for decision-ready evidence generation.